# IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE:

: MDL NO. 07-MD-1871

AVANDIA MARKETING, SALES PRACTICES AND : Philadelphia, Pennsylvania PRODUCTS LIABILITY LITIGATION

: July 3, 2012

: 9:32 a.m.

TRANSCRIPT OF HEARING BEFORE THE HONORABLE CYNTHIA M. RUFE UNITED STATES DISTRICT JUDGE

#### APPEARANCES:

For the Plaintiff's JOSEPH J. ZONIES, ESQUIRE Steering Committee: Reilly Pozner, LLP 1900 Sixteenth Street Suite 1700 Denver, CO 80202

> DIANNE M. NAST, ESQUIRE RodaNast, PC 801 Estelle Drive Lancaster, PA 17601

THOMAS P. CARTMELL, ESQUIRE Wagstaff & Cartmell, LLP 4740 Grand Avenue Suite 300 Kansas City, MO 64112

VANCE R. ANDRUS, ESQUIRE Andrus, Hood & Wagstaff, PC 1999 Broadway Suite 4150 Denver, CO 80202

Transcribers Limited 17 Rickland Drive Sewell, NJ 08080 856-589-6100 • 856-589-9005

	······································		
			2
1	APPEARANCES:	(Continued)	
2	For the Respondents:	ROBERT L. SACHS, ESQUIRE JASON TUCKER, ESQUIRE	
3 4		Shrager, Spivey & Sachs 2300 One Commerce Square 2005 Market Street	
5		Philadelphia, PA 19103	
6			
7	Audio Operator:	Erica Pratt	
8	Transcribed By:	Jeff Nathanson	
9 .			
10	Proceedings recorded by electronic sound recording; transcript produced by computer-aided		
11	transcription service.		
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
			Ì

```
3
 1
               (The following was heard in open court at
 2
     9:32 a.m.)
 3
               THE COURT: Good morning, everyone.
 4
                     Good morning, Your Honor.
 5
               THE COURT: Let's take roll call. Who do we
 6
     have here on behalf of the plaintiffs' steering
 7
     committee? Mr. Zonies.
 8
               MR. ZONIES: Your Honor, Joe Zonies on behalf
9
     of the advisory committee. With me is Tom Cartmell and
10
     Vance Andrus also with the committee.
11
               Bryan Aylstock sends his regards, as does
12
     Steve Corr who could not be here today, and again Dr.
13
     Zonies is in the courtroom.
14
               THE COURT: And Dianne Nast?
15
               MR. ZONIES: Dianne Nast, we found her, was
16
     in the hallway going back to visit with the Court.
17
               THE COURT: Very good. On behalf of the
18
    Heninger Garrison firm?
19
               MR. SACHS: Your Honor, again Robert Sachs
20
     and my associate, Jason Tucker from Shrager, Spivey &
21
     Sachs here in Philadelphia for Heninger Garrison Davis.
22
               THE COURT: And I understand the video
23
    conference is set up and we have someone named Mr.
    Garrison on the other end?
24
               MR. SACHS: Lou, are you in the other room?
25
```

```
4
 1
               MR. GARRISON: Yes, I'm here.
 2
               MR. SACHS: Okay. Can you go sit in that
 3
     chair so we can all see you, please?
 4
               MR. GARRISON: Considering I am in the one
 5
     that they told me to sit in, let me see. Is this it?
 6
               THE COURT: That is a better one.
 7
               MR. SACHS: You are much better over there.
 8
               MR. GARRISON: Okay.
 9
               MR. SACHS: If you move a little bit to your
10
     right you will be more centered on the screen that we
11
     see.
12
               THE COURT: That's just about perfect, Mr.
13
    Garrison, thank you.
14
               MR. GARRISON: Thank you.
15
               THE COURT: I'll get back to you in a moment,
16
    Mr. Garrison. May I know who is here on the record,
17
    because I do have eyes, for GSK?
18
               MR. ZUCKER: Yes. Good morning, Your Honor.
19
    Ken Zucker representing GlaxoSmithKline.
20
               MS. GUSSACK: Nina Gussack, Your Honor.
21
               THE COURT: Good morning.
               MS. GUSSACK: Good morning.
22
               THE COURT: Would you like to sit up with Mr.
23
24
     Zucker?
               MS. GUSSACK: I think I would, Judge, thank
25
```

you.

I appreciate that.

concern, how is your father, Mr. Garrison?

MR. GARRISON: Thank you very much, Your

Honor. He is been transported to the nursing home and

THE COURT: Thank you. Now, we are ready to

I would like to ask first, because I do have

continue to improve. Thank you for asking, Your Honor,

now he is in a nursing home, so hopefully he will

THE COURT: Well, you're welcome. We missed your presence yesterday. We did not expect that you would not be here, sir. We could not admit the affidavit in your place. Counsel on behalf of the plaintiffs' steering committee agreed that we could proceed today by video conference.

It is most important that we address the important matters that are here, notwithstanding the difficulties that you have in your family, and everyone else actually has family commitments, but they are no quite the same as what you are going through. So, the Court does have care and concern, I want you to know that.

MR. GARRISON: I appreciate that.

THE COURT: All right. So, where are we?

MR. SACHS: Your Honor, may I make a brief

offer of proof that I think will, I hope, expedite matters somewhat? Robert Sachs again on behalf of the Heninger Garrison Davis firm.

In consultations with counsel yesterday after we adjourned for the day, and Mr. Garrison is prepared today to acknowledge a couple of important matters.

First is the jurisdiction of this Court based on his endorsement of the form PTO 10 protective order, even though the form that he signed is the PTO 10 protective order which has language which you will acknowledge submits this case to this Court's jurisdiction.

Secondarily, he is prepared to acknowledge that under PTO 70, because the PTO 10 protective order was signed, that he will authorize the release of the seven percent common benefit contribution for the fees of the Heninger Garrison cases. That seven percent is currently residing in a qualified settlement fund in Alabama.

So, for obvious reasons I think that will shorten to a large extent, but we are prepared to go through that testimony with Mr. Garrison so that the Court has a record on which to find, of course.

But, I hope that will at least curtail these proceedings somewhat at this point.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

THE COURT: In other words, Mr. Garrison on behalf of his clients and his firm is now agreeing, in fact, stipulating that all of his cases, did I hear that correctly, all of his cases are subject to the seven percent assessment?

7

MR. SACHS: Yes, Your Honor, because that's the way the common benefit fee is collected. It is seven percent on all, is it 503 or 504 cases, Lou?

(No response heard.)

MR. SACHS: All of the cases, though, and we intend it to mean all of the cases.

THE COURT: All right. I think we should get affirmation on the record, and if this is the sum and total of the stipulations and agreements I would like to know what else the PSC thinks is necessary, because we do have to have a record upon which to accept this agreement.

I believe that this will be a final ruling if there is no counter to this evidence. Mr. Zonies, go ahead.

MR. ZONIES: Your Honor, I would appreciate the opportunity to visit with my co-counsel, but I think after taking the evidence we will have a better sense of whether or not that satisfies us.

We appreciate the offer of proof, and

```
PENGAD - 1-800-631-8989 • www.pengad.com
  FORM 2094
```

25

8 1 assuming the evidence comes in in that fashion I would 2 then suspect that we may be able to catch earlier 3 flights. 4 THE COURT: Let's work on it. 5 MR. ZONIES: Depending on what else the Court 6 would like. 7 THE COURT: Let's work on it, because if 8 there's an admission to what I just heard, the 9 acknowledgement of the endorsement, the signature, et 10 cetera, and further, no argument to the contrary that 11 these agreements cause Mr. Garrison's cases and his 12 firm's cases, all 503 or 504 of them, whatever that may 13 be, to be subject to the MDL's jurisdiction and the 14 assessment of the common fund at seven percent on each 15 of those cases. 16 That would seem to ratify the position of the 17 PSC. But, we'll let you confer with your colleagues as 18 to whether or not anything else is necessary. In any event, we'll have Mr. Garrison sworn. 19 20 We accept your offer of proof, let's proceed. MR. SACHS: Your Honor, may I request the 21 Court's permission just to question the witness from 22 counsel table? 23

THE COURT: Yes, you may.

MR. SACHS: Thank you.

```
9
 1
               WILLIAM GARRISON, Respondents' Witness,
2
     Sworn.
 3
               COURTROOM DEPUTY: Please state your full
4
    name and spell your last name for the record.
5
               THE WITNESS: William Lewis Garrison, Jr.
6
               THE COURT: You may proceed.
7
                        DIRECT EXAMINATION
8
    BY MR. SACHS:
        Mr. Garrison, you have just stated your name for
10
    the record. Would you state your title within your law
11
    firm, sir?
12
        I am a shareholder of Heninger Garrison Davis, LLC.
       And where is that firm based, sir?
13
        Our primary office is in Birmingham, Alabama.
14
15
    have offices here in Atlanta where I am now, New York,
16
    and New Jersey.
         Sir, did your firm represent plaintiffs in
17
    litigation against GSK regarding drug product liability
18
19
    for the drug Avandia?
        We did.
20
    Α
        And sir, where were those cases ultimately filed?
21
         The cases that were filed were all filed in state
22
23
    court in Alabama.
        And to your knowledge, sir, have those cases now
24
    been settled with GSK?
25
```

# Mr. Garrison - Direct

A The ones that were eligible for settlement under GSK's criteria have been settled. The ones that were not have not been settled.

Q Of course. For those settled cases was there a settlement fund created, identified as a qualified settlement fund?

A There was initially a settlement fund created for a qualified settlement fund that we established in Jefferson County, Alabama for 679 claimants.

After the vetting process established by GSK that ultimately whittled down to 503, and then we had a couple of dual-rep issues, and now the number -- and Mr. Zucker can confirm, but I believe it's 502.

So, that is our total settlement number of claimants right now.

Q And without giving any confidential numbers that your firm has agreed with GSK to not express in open court in any manner other than in a sealed document, would you explain where the settlement funds are at this time for those cases you have just identified?

A Well, the funds that have not been disbursed -- I mean, all of the seven percent money is still in the bank, First Commercial Bank which is based in Birmingham.

Some of the money, of course, pursuant to our

Mr. Garrison - Direct

11

25

1 fulfillment of our obligations of the MSA has been 2 distributed. But, all of the money, the common benefit 3 money has been withheld 4 Mr. Garrison, in conjunction with your 5 representation of clients, in particular under the 6 caption of Shirley Battle as personal representative of 7 the estate of Philip Battle, et al, Cert Court of 8 Jefferson County, Alabama, Case Number CV-2009-903739, 9 did you stipulate to the entry of a protective order 10 along with counsel for GSK, Joseph P.H. Babington? 11 I did, I signed it. 12 And sir, as part of signing that are you aware that 13 there was, and we will offer the stipulated protective 14 order as Exhibit Garrison 1 in just a moment, as part 15 of that, sir, are you aware that the order from the court recites that it was the protective order that was 16 17 entered in In Re: Avandia marketing, sales practices and products liability litigation MDL Number 1871? 18 Yes. 19 Sir, this stipulated protective order also recited 20 that "Counsel for plaintiffs and defendants have signed 21 and executed the endorsement of protective order that 22 is also attached to this stipulated protective order." 23 24 Is it your acknowledgement -- do you acknowledge today that you also signed that endorsement

20

21

22

23

24

25

Mr. Garrison - Direct 12 1 of the protective order? 2 Yes, that would be my signature that's on there. 3 Sir, do you also agree that the endorsement of that 4 protective order contains the following sentence on 5 page 17? 6 "I agree to be subject to the jurisdiction of 7 the United States District Court for the Eastern 8 District of Pennsylvania for the purposes of any 9 proceedings relating to enforcement of the order." 10 Yes, it does. 11 Sir, having signed that protective order which is 12 attached to the stipulated order which we are going to 13 offer today as Exhibit Garrison 1, are you also aware 14 that this Court's pretrial order 70 contained a 15 paragraph 3(b) that defines covered claims to include 16 those where attorneys who executed the endorsement of 17 protective order attached to pretrial order number 10, those are covered claims under PTO 70? 18

A I am certainly aware of that now.

Q Sir, given that those items that I have just gone over with you, both the language in the stipulated protective order, which adopted in its entirety PTO 10, and the language of PTO 70, are you prepared at this time to represent to this Court that you will authorize the release of the seven percent common benefit fund

Mr. Garrison - Direct 13 1 contribution for the 503 cases from the Heninger 2 Garrison firm that you've identified today? 3 Yes. I will do whatever I have to do to get those 4 funds, the seven percent released and transferred to 5 whatever the account Judge Rufe deems necessary. 6 MR. SACHS: Nothing further on behalf of the 7 Heninger Garrison Davis firm. 8 THE COURT: Thank you. Mr. Zonies, do you 9 have any cross-examination for Mr. Garrison? 10 MR. ZONIES: May I take a moment with my 11 co-counsel, Your Honor? 12 THE COURT: Yes, you may. I will also be 13 asking GSK if they have any questions to pose. 14 MR. ZONIES: Thank you. 15 (Pause in proceedings.) 16 MR. ZONIES: Your Honor, the consensus of the 17 committee is that in part we would ask the Court that 18 if that is sufficient information I would make an offer 19 of proof that we can demonstrate the use in a number of 20 ways of other MDL work product beside Mr. Garrison's discussion about using PTO 10, which obviously was work 21 22 product as he has acknowledged. 23 There are other pieces of work product that we can demonstrate if the Court would find that 24

necessary or helpful in the Court's jurisdictional

## Mr. Garrison - Direct 14 1 analysis. 2 However, absent that I think we believe that 3 that's a sufficient predicate for the Court under our 4 understanding of the law. 5 THE COURT: Could you make an offer of proof 6 on that work product and as it relates to 7 cross-examining Mr. Garrison? 8 MR. ZONIES: I can. 9 THE COURT: It may be a more complete record 10 if we proceed even briefly with an offer of proof. 11 think Mr. Sachs' method there was expeditious as well 12 as thorough, and sufficient as far as it goes. 13 But, since we are trying to make a full 14 record here for purposes of MDL management I think it 15 is important that we have all of the facts out on this 16 record. 17 MR. ZONIES: Thank you, Your Honor. It may 18 be better, Your Honor, if I go ahead and cross Mr. 19 Garrison on these issues then. 20 THE COURT: As you are comfortable with 21 proceeding, Mr. Zonies. 22 MR. ZONIES: Thank you. CROSS-EXAMINATION 23

BY MR. ZONIES:

24

25

Q Good morning, Mr. Garrison.

24

25

# Mr. Garrison - Cross 15 1 Good morning, Mr. Zonies, how are you? 2 I'm doing well. I was about to say I'm Mr. Zonies, 3 but it appears you know that. Mr. Garrison, you have 4 been involved in mass tort litigation for a number of years, isn't that true? 6 Yes, sir. A 7 And you have an understanding that document such as 8 PTO 10, the protective order in this case that were 9 negotiated and created by this PSC, it takes a 10 significant amount of work on the PSC's behalf and on 11 GSK's behalf to negotiate such documents before they 12 are finalized, isn't that true? 13 Yes, sir, I can. And you would say that that's also true, for 14 example, for something like the tolling agreement that 15 was utilized by you on behalf of your clients in this 16 17 case, as well? Are you asking me my opinion on how much time that 18 took to negotiate the tolling agreement? I just don't 19 20 know how much time it took. And your use of the tolling agreement in this case, 21 Mr. Garrison, was in response to discovery from GSK to 22 your clients, is that fair?

Well, we filed, I think there was 71 cases in state

court, and then we reached an arrangement with GSK that

#### Mr. Garrison - Cross

we would toll a lot of those cases, and rather than just kind of jumble up the docket, and that's what we did. That's my understanding of how it wound up that we ended up tolling some of our cases.

- Q Correct. Initially, you tolled 172 of your clients' cases, correct?
- A I think that sounds right.
- Q That's from the affidavit you filed in this Court yesterday, yes?
- 10 A Yes, sir.

- Q And you have stated in that affidavit that you did not have knowledge that execution of those tolling agreements on behalf of your clients would trigger PTO obligation, that's what you stated in you affidavit, correct? I'm sorry, PTO 70 assessment obligation.
- A I think what I said was it's some of those, and I believe about half of my tolling agreements were executed before PTO 70 even came into place.
- Q I understand. So, your position with regard to those half were that you didn't have knowledge that that might trigger an assessment, correct?
- A Well, I didn't have knowledge because PTO 70 had not been entered yet on that number of cases.
- Q I understand. PTO 7, however, had been entered.

  Did you review PTO 7 which approved the tolling

23

24

25

Mr. Garrison - Cross 17 1 agreements prior to utilizing the tolling agreements? 2 Sir, all we did was execute the tolling agreements 3 that were sent to us by GSK. Again, we were all in 4 state court in Alabama and I didn't go review the MDL 5 docket for Avandia. So, no, sir. 6 So, then you were not aware at the time that PTO 7, 7 which approved the form of the tolling agreement, 8 stated as follows. 9 "As the form of tolling agreement represents 10 the combined efforts and work of the plaintiffs' 11 steering committee, all parties are placed on notice 12 that those availing themselves of its provisions, 13 together with all of those parties otherwise subject to 14 the jurisdiction of this multi-district litigation, 15 shall be subject to such common benefit assessment, if 16 any, as this Court may order in the future." 17 No, sir, I didn't get into how and why the tolling 18 agreement came into place, I just reviewed it and 19 signed it. And PTO 7 the, sir, you don't know that was entered 20 21 on June 9th, 2008?

A No, sir, I did not.

Q Putting all attorneys who used the tolling agreement that was negotiated and worked on, and as the Court stated in PTO 7 was "The work of common benefit

Mr. Garrison - Cross 18 1 attorneys in this litigation putting all such attorneys 2 and their clients on notice that use of that tolling 3 agreement would subject them potentially to a common 4 benefit assessment." You did not know that? 5 I didn't know it. I don't think the tolling 6 agreement itself referenced that PTO, but in any event, I did not review the -- like I said, I did not review 7 the MDL pleadings or website to ascertain any 8 9 background about how the tolling agreement came into 10 place. You will say that that was available on the Court's 11 12 website, it did not even require ECF access, correct? I assumed it was available. I just didn't feel 13 14 that since I was trying to keep my cases in state court 15 I didn't feel that I needed to try to consult the 16 website. Now, you have stated earlier that you indeed 17 executed the endorsement to PTO 10, correct? 18 Yes, sir. 19 You executed to endorsement to PTO 10, or at least 20 the court-approved that stipulated PTO 10 on or about 21 April 30th of 2010, correct? 22 I believe that's correct. 23 Α Now, your execution of PTO 10 was in response to 24 your earlier service of discovery on GlaxoSmithKline, 25

#### Mr. Garrison - Cross

19

1 correct?

2

3

4

5

6

7

8

9

15

19

20

21

22

Well, the attorneys for GSK would not provide any documents to me until I signed the -- or agreed to use a protective order that was being used in the MDL. was told that explicitly by them and that there was no negotiation on that point.

- And on January 28th of 2010, the same year that you settled your cases, you served discovery on GSK on behalf of all of your clients, correct?
- 10 Well, on behalf of the clients that had been filed, 11 yes, sir.
- And in response, as you stated, GSK offered to 12 13 provide you with a duplicate of PTO 10 to execute in 14 order to get that discovery, correct?
  - They not only offered, they demanded it.
- 16 0 And --
- That's the only way they would give me any 17 18 documents.
  - You needed that discovery, sir, to make it more likely that you, as an attorney for their clients, could pursue their cases more effectively and push forward to a better resolution for your clients, correct, that's why you served that discovery in
- 23
- 24 January?
- Yes, sir, I served it just for the same reasons 25

Mr. Garrison - Cross 20 1 that we all try to get their documents. Unfortunately, 2 I never got any. 3 But, the purpose of your serving that discovery in 4 January was to get the discovery and their documents, 5 correct? 6 Oh, yes, sir, sure. 7 For the benefit of your clients? 8 That was my goal. 9 Now, in response, upon execution of PTO 10 did GSK 10 produce those documents to you? 11 No, sir, they kept dragging around and they never 12 would produce them. 13 Now, the documents you were seeking, do you have 14 any sense of how GSK determined which documents it was 15 required to produce under your agreement? Well, I don't have my discovery right now. 16 17 it was quite voluminous. But, at one point they had agreed to put everything on, I believe, a hard drive. 18 We kept going back to them saying when's this 19 going to be produced, and then they wanted to charge us 20 21 for the hard drive, but they never got it to us. So, I don't know what documents they had on 22 there and whether or not there was ever, in fact, a 23 hard drive because it was never produced to us. 24 25 So, you don't --

#### Mr. Garrison - Cross

A But, we were trying to get the documents, sir.

Q You don't know, for example, if the documents that GSK was about to produce to you if you had executed PTO 10 were documents that were gathered and given to the MDL in response to the PSC's discovery request, you don't know if that's what those documents were, correct?

A Well, I never saw the documents, so I don't know what the documents were. I do know that at least they referenced to me in e-mails that they were producing some part or perhaps --

I don't know what portion of the documents were produced in the MDL, but I believe my discovery requests may have been more expansive, to include things that may not have been produced in the MDL.

But, to answer your question, I don't know where the documents were because I never got them.

Q And you don't know, for example, whether those documents included documents that the PSC fought for over six months to get the documents de-privileged, you don't know whether or not those documents were coming to you, right?

A Sir, I wish I had seen the documents, but they never gave them to me.

Q And you --

#### Mr. Garrison - Cross

22

- 1 A So, I never got them for signing the PTO.
- 2 Q And you don't know that those documents included
- 3 documents that the PSC extensively briefed on the issue
- 4 of privilege, held multiple hearings in front of
- 5 | Special Master Shestack regarding privilege, and that
- 6 the special master issued a ruling and recommendation
- 7 after those hearings, correct?
- 8 A Mr. Zonies, I have no way of knowing. Again,
- 9 because I didn't see the documents.
- 10 Q So, you similarly have no way of knowing whether or
- 11 not it included documents that subsequently were the
- 12 subject of an appeal to this Court over Special Master
- 13 | Shestack's ruling and recommendation, and that that was
- 14 fully briefed and argued before this Court, and that
- 15 | this Court issued an order about those documents,
- 16 | correct?
- 17 A Mr. Zonies, I don't what the documents were.
- 18 | Again, I have no idea, I never got them.
- 19 O And you don't know whether or not it included the
- 20 | nearly 90 percent of those privileged claim documents
- 21 that were eventually de-designated, correct?
- 22 | A I'm sorry, sir, I couldn't -- de-designated what?
- 23 | Q That the documents --
- 24 A I couldn't understand.
- 25 Q The privileged designation on the documents were

## Mr. Garrison - Cross 23 1 subsequently removed and those documents became part of 2 the documents in this MDL? 3 I don't know. I wish I could answer that because I 4 wish I had seen them, but I never did. 5 And to get those documents all you had to do was 6 sign PTO 10, correct? 7 It wasn't that easy, apparently, because I never 8 got them. 9 Well, you agreed to execute PTO 10 and it was filed 10 in April. You subsequently, on behalf of yourself and 11 your clients, filed a motion to compel production of 12 those documents, is that correct? 13 Yes, sir, because they kept dragging around. 14 wouldn't give them to us even though I signed that 15 protective order. 16 And on July 7th, 2010, you filed a motion to compel 17 production of those documents, correct? 18 If that's what the record reflects yes, sir. know we did file a motion to compel because they would 19 20 not produce them. 21 Correct. In that motion to compel you stated as 22 "Through a series of telephone calls and e-mails GSK agreed to produce all discovery and 23 documents which has been conducted in the MDL, which 24

consists of approximately 13 million pages."

21

22

23

24

25

## Mr. Garrison - Cross 24 1 Does that sound like something you would have put in that motion to compel, sir? 3 Yes, sir. 4 "And prior to producing the documents," the motion 5 continues, "GSK required plaintiffs' to consent to 6 stipulated protective order which was exactly like the 7 one entered by the federal court in the MDL 8 proceedings." That's also in your brief on July -your motion on July 7th, 2010, correct? 10 Yes, sir. 11 You believe this was a valid factually and legally 12 sound motion, correct? 13 Mr. Zonies, they kept telling me they were going to 14 produce the documents. They never did. I wanted 15 whatever documents I could get. I knew I had signed 16 the MDL protective order, and I tried to get the documents. I tried, but they wouldn't produce them to 17 18 me, so I filed a motion to compel. 19 And as you --0

- A And they had told me there were 13 million or some-odd pages, and that's what I was trying to get.
  - Q And as you stated earlier, you wanted those documents and that discovery to put you and your clients in a better position in the litigation, to prosecute or settle the litigation, correct?

#### Mr. Garrison - Cross

A If I had any documents from whatever source, whether it was MDL or documents that weren't produced in the MDL that were in my discovery request, I though that would help me litigate our cases.

Q And here we're talking about the 13 million pages that were generated in this MDL. You would have found those very beneficial to you to prosecute or settle your cases with GSK if you were able to get all those documents, yes?

A You cut out a little bit there, Mr. Zonies, but I think I got where you're going. Yes, sir, I would hope I would, that's why I was trying to get them.

Q In fact, you have represented in your affidavit in this case that ten days later on July 17th of 2010 you received the first draft of the master settlement agreement, ten days after you filed your motion to compel production of those documents, correct?

A Well, in fact, we had been negotiating settlement with GSK even in June and, you know, we had already agreed on the numbers and the per case average of the cases.

It had to be right about the same time we filed that motion. So, that's my recollection, because I know I got the first draft of the MSA from Ken on July 17th and, of course, there had to be, you know, at

```
Mr. Garrison - Cross
                                                            26
 1
    least some lag time between the time we struck our deal
 2
    and the time we got that. So, we never did get the
 3
    documents, and then we settled our cases.
 4
               (Pause in proceedings.)
 5
               MR. ZONIES: Your Honor, may I approach to
 6
    deliver to the Court a copy of that motion to compel?
7
               THE COURT: Yes, please.
8
               MR. ZONIES: And move it into the record.
9
               THE COURT: Has Mr. Sachs seen it?
10
               (Pause in proceedings.)
11
               THE COURT: Thank you. PSC-1?
12
               MR. ZONIES: PAC-1, plaintiffs' advisory
13
    committee, Your Honor.
14
               THE COURT: Thank you.
15
               (Pause in proceedings.)
16
    BY MR. ZONIES:
17
        Mr. Garrison, I think we've established that you
18
    utilized on your behalf and the behalf of your clients
19
    the MDL negotiated and entered tolling agreement, yes?
20
        We used the tolling agreement, yes, sir.
21
        That you utilized on behalf of yourself and your
22
    clients the MDL negotiated and entered PTO 10, correct?
23
         I'm not quite sure what you mean on PTO 10, Mr.
24
    Zonies.
25
        Well, that was drafted by the MDL and negotiated by
```

production.

25

Mr. Garrison - Cross 27 the MDL with GSK, and you utilized that on behalf of 1 2 yourself and your clients, correct? 3 Are you talking about the tolling agreement? 4 No, PTO 10, the protective order to seek documents? 5 Oh, yes, sir. Yes, sir, I'm sorry, correct. 6 That's --0 We did sign it. Unfortunately, to no avail, but we 7 8 did. 9 Okay. 10 I did. Α And there were actually other documents from this 11 MDL that were negotiated by the PSC and GSK that you 12 utilized on your behalf and on behalf of your clients, 13 14 correct? 15 Such as? Α Q For example you, in response to GSK's discovery on 16 your clients, you utilized the plaintiffs' fact sheets 17 that were negotiated and created in this MDL, and you 18 downloaded those from this MDL's website to utilize 19 those plaintiffs' fact sheets in response to GSK's 20 discovery in your clients' cases, correct? 21 Well, again, that was a recommendation that GSK's 22 lawyers made to us rather than just go through all the 23 usual discovery, and interrogatories, and requests for 24

## Mr. Garrison - Cross

28

They suggested why don't you guys just answer

the fact sheets that we had agreed to use in the MDL,

and we did.

- Q You did, in fact, do that, correct?
- 5 A At their insistence. At their insistence yes, sir,
- 6 | we did.

1

4

- 7 Q And you, in fact, downloaded those in an editable
- 8 format from this Court's website in order to utilize it
- 9 in your cases, correct?
- 10 A Now, Mr. Zonies, I can't tell you how we got them.
- 11 That could have been the way we got them, but I don't
- 12 know how we got those.
- 13 O That answer is --
- 14 A I don't remember that.
- 15 | Q -- above your pay grade, you weren't filling them
- 16 | out?
- 17 A I hope that was below my pay grade, but I just
- 18 can't recollect. I'm not trying to evade your
- 19 question, I just don't know how we got those fact
- 20 | sheets, I don't.
- 21 | Q I understand. But, you would admit that those were
- 22 the fact sheets that were negotiated and agreed to in
- 23 this MDL by the PSC and GSK, yes?
- 24 A We are in agreement on that, yes, sir.
- 25 MR. ZONIES: If I may have a moment, Your

```
Mr. Garrison - Cross
                                                            29
 1
    Honor?
 2
               THE COURT: You may.
 3
               (Pause in proceedings.)
 4
               MR. SACHS: Can we have just one minute?
5
               THE COURT: Of course.
 6
               (Pause in proceedings.)
7
               MR. ZONIES: May I approach, Your Honor? We
8
    have a substitution on what was handed to the Court.
9
               THE COURT: Yes, you may. Mr. Sachs, I
10
    haven't forgotten that you wanted to move a document
11
    in, as well.
12
               MR. SACHS: Thank you, Your Honor.
13
               (Pause in proceedings.)
14
               MR. ZONIES: So, Your Honor, we also would
15
    move for admission of the motion to compel by GSK,
16
    wherein the plaintiffs' fact sheets that were utilized
17
    by the firm were attached, and also the -- we would
18
    join Mr. Sachs in the offer on the stipulated
19
    protective order, as well.
20
               MR. SACHS: Permission to approach, Your
    Honor, to deliver the stipulated protective order to
21
22
    the Court?
               THE COURT: Yes, thank you.
23
24
               MR. ZONIES: Also, Your Honor, we would move
    as PAC -- let's do this in order. PAC-2, the Pretrial
25
```

```
30
                       Mr. Garrison - Cross
1
    Order Number 7.
2
               (Pause in proceedings.)
3
               MR. ZONIES: PTO 7 being the pretrial order,
    Your Honor, that contains the language about the
4
5
    tolling agreement representing the common benefit work,
6
    and putting attorneys and clients on notice of the
7
    assessment associated with the use of that.
8
               (Pause in proceedings.)
9
               MR. ZONIES: Your Honor, as to PTO 70 we
10
    would just ask that the Court take notice that that is
11
    in the court record.
               THE COURT: We can.
12
13
               MR. ZONIES: Thank you. We will supplement
14
    with the motion to compel of GSK containing the
    plaintiffs' fact sheets as PAC-3, as soon as we find
15
    it.
16
               THE COURT: All right. I haven't seen that
17
    myself. All right. With that, are there any
18
    additional questions?
19
               MR. ZONIES: That's it for us, Your Honor.
20
               THE COURT: Thank you. I would like to ask
21
    GSK to pose any questions it might deem appropriate.
22
               MS. GUSSACK: We have no questions, Your
23
    Honor.
24
               THE COURT: Thank you. You will have a
25
```

```
31
                       Mr. Garrison - Cross
1
    chance at redirect.
2
               MR. ZONIES: May I approach with the motion
3
    to compel, Your Honor?
4
               THE COURT: Yes.
5
               (Pause in proceedings.)
6
               MR. ZONIES: So, to summarize what has been
7
    proffered, Your Honor, we have Heninger Garrison
8
    Exhibit 1, which is the stipulated protective order
9
    entered in the court in Alabama containing PTO 10.
10
               PAC-1, which is the motion to compel of
11
    Heninger Garrison in Alabama, seeking to compel
12
    production of the 13 million pages of discovery from
13
    the MDL.
14
               PAC-2, which is Pretrial Order Number 7,
15
    containing language about notice of a potential
16
    assessment associated with the use of the tolling
17
    agreements.
18
               Then, PAC-3, which is the motion to compel of
19
    GSK attaching fact sheets generated from this MDL used
    by Mr. Garrison on behalf of his clients.
20
               We would move for admission of all of those
21
22
    on the PAC side.
23
               THE COURT: Any objection, Mr. Sachs?
               MR. SACHS: No objection, Your Honor.
24
               THE COURT: All right. Those PSC documents
25
```

```
Mr. Garrison - Cross
                                                            32
 1
     are, therefore -- there's no objection from GSK, I
 2
     assume?
 3
               MS. GUSSACK: No, Your Honor.
 4
               THE COURT: All right. They are admitted,
 5
     along with the Heninger Garrison's 1 document, that is
 6
     the stipulated protective order and endorsement.
 7
               (Plaintiffs' Exhibit PAC-1, motion to compel,
 8
     PAC-2, PTO 7, and PAC-3, motion to compel, are admitted
 9
     into evidence.)
10
               (Respondents' Exhibit Garrison 1, protective
11
     order, is admitted into evidence.)
12
               MR. ZONIES: Thank you, Your Honor.
13
               THE COURT: All right. With that, Mr. Sachs,
14
    do you have any redirect?
15
               MR. SACHS: Very briefly, Your Honor.
16
               THE COURT: Proceed.
17
                       REDIRECT EXAMINATION
    BY MR. SACHS:
18
19
        Mr. Garrison, you have been asked a number of
20
    questions about MDL documents used in your Alabama
     litigation. Sir, when you filed your cases in Alabama
21
22
    what steps were taken by GSK regarding the court in
    which those cases would be pending?
23
        You cut out, I'm sorry, Rob. Just very briefly,
24
    what steps were taken what?
25
```

25

Mr. Garrison - Redirect 1 By GSK regarding the court in which those cases 2 would be pending, and to the point, without leading you 3 too much, was there an effort at removal to federal 4 court? 5 Well, there was never an effort to remove at that 6 point because at the time there was a case in the 7 Eleventh Circuit, Lowery versus Alabama Power Company, 8 that enabled us to keep the cases in state court. 9 Now, there was a lot of activity by GSK to 10 get us to, you know, try to admit that the amount of 11 controversy was over \$75,000, so that was a subject of 12 a lot of motions. 13 There were also a lot of motions and hearings 14 about severance, because we had filed them in certain 15 venues. We would try to push them in these venues. 16 So, there was certainly efforts by GSK, in 17 fact a significant amount of efforts by GSK to, I 18 guess, defeat our strategy of keeping cases at state 19 court. 20 Of course, they were not successful, but they 21 certainly tried, although they knew that if it was 22 removed under the present, at that time the Lowery v Alabama Power case, they would be remanded. So, they 23 never did remove them. 24

I want to be abundantly clear about a point you've

24

25

Mr. Garrison - Redirect 1 made several times. Despite having signed a protective 2 order that was given to you by GSK, was there any 3 negotiation of the terms of that protective order, by 4 the way? 5 No, I questioned it. Whether or not that's 6 something that they needed, and they were insistent on 7 that, that if we wanted to get the documents we would 8 have to use the protective order that was used in the 9 MDL. 10 Frankly, you know, I reviewed the terms of 11 the protective order. I mean, the terms were fine, and 12 so it didn't matter to me whether it was produced in 13 the MDL or not. I was just trying to get documents. 14 So, no, they wouldn't negotiate it. 15 My point exactly. Mr. Zonies has asked you about 16 the protective order and asked you about your experience in other mass court litigation, was that 17 18 protective order very similar, in terms of the types of documents that would be considered protected documents, 19 to what you had seen in the many other mass torts in 20 21 which you had worked? 22 Well, I can only answer by stating that given my 30 years of law practice, and probably the last 15 to 20 23

doing mass tort and pharmaceutical litigation, there's

usually a tolling agreement which is very similar to

Garrison.

25

```
Mr. Garrison - Redirect
                                                            35
 1
     one that was done in the Avandia litigation.
 2
               There is usually one in every case. Not all
 3
     the time, but I certainly have seen them and used them
 4
    before.
 5
        How about the protective order? When you reviewed
 6
     that when it was proposed to you by counsel for GSK did
 7
    you find that that protective order, as well, was very
 8
     similar to ones you have seen in many other mass torts
 9
     in your 15 to 20 years of experience handling cases
10
    like that?
11
         Sure, it's very similar to the ones that I am doing
12
    right now. Yes, sir, very similar.
13
        And you continue to be actively involve din mass
14
    tort litigation?
15
    Α
        I certainly do.
        Have you been privileged, sir, to be named by the
16
17
    court to serve on plaintiffs' steering committees in
18
    other MDLs?
19
        Well, presently I am on the plaintiffs' steering
    committee in the Kugel Hernia Mesh MDL pending before
20
    the Honorable Mary Lisi up in the District Court of
21
    Rhode Island. Also, on the Levaquin MDL pending in the
22
    District Court of Minnesota.
23
               MR. SACHS: Nothing further. Thank you, Mr.
24
```

what we agreed to do.

Mr. Garrison - Redirect 36 1 THE WITNESS: Thank you. 2 THE COURT: Anything further, Mr. Zonies? 3 MR. ZONIES: Quickly, Your Honor. 4 RECROSS-EXAMINATION 5 BY MR. ZONIES: 6 Mr. Garrison, you spoke of motions to sever and to 7 dismiss a number of cases in Alabama, do you recall 8 that? Yes, sir. 10 In fact, those cases were indeed severed and 11 dismissed, and those cases are the ones where you used 12 the tolling agreement, correct? 13 I know there was some cases severed. I think there 14 was one sent to Greene County, Alabama, and there was 15 another one sent to Montgomery County, Alabama, and I 16 think we ultimately agreed with that. 17 But, you know, and then we dismissed a lot of 18 them because we targeted five or six that we wanted to 19 push. So, we agreed to dismiss the rest of them and 20 put them on tolling agreements, yes, sir. 21 Correct, you dismissed them and then utilized the 22 tolling agreement to protect the statute for those 23 cases, correct? 24 Well, that's what they offered to do, so that's

```
Mr. Garrison - Recross
                                                           37
1
        And there's an MDL assessment in Kugel Mesh and
2
    Levaquin, correct?
3
        There's an assessment, but of course no
4
    distributions have been made yet.
5
        But, you are aware that in MDLs and mass tort
6
    litigation typically there is also an assessment,
7
    yes?
8
        Oh, yes, sir, sure.
9
              MR. ZONIES: Nothing further, Your Honor.
10
               THE COURT: Does GSK have any follow-up
11
    questions?
12
              MS. NAST: No, Your Honor.
13
               THE COURT: Was there anything to ask Mr.
    Garrison about concerning the referral source of cases,
14
    because once we lose him I don't want to reconvene.
15
16
              MR. SACHS: I'm happy to cover that, Your
    Honor. Let me just pull out the affidavit.
17
18
               THE COURT: I'm not telling counsel what to
19
    do, direct, or redirect, or cross. I just want to be
    sure that we have a complete record of what is
20
    essential here.
21
               MR. SACHS: With permission to proceed again
22
    on behalf of the Heninger Garrison firm, Your Honor?
23
               THE COURT: Please, Mr. Sachs, you may
24
    proceed.
25
```

## Mr. Garrison ~ Recross

REDIRECT EXAMINATION

BY MR. SACHS:

Q Mr. Garrison, sir, one of the referral sources for the Avandia cases which you have filed was an attorney names Jesse Ferrer, F-E-R-R-E-R, from the law firm of Ferrer, Poirot, P-O-I-R-O-T, & Wansbrough from Dallas,

7 Texas, is that correct, sir?

A Yes, Jesse sent us a number of cases.

Q Sir, do you have any reason to dispute the fact that of the cases you've settled with GSK, 295 of the cases he referred to you were ultimately included in your firm's Avandia settlement group?

A That's true. Of the present settlement number, 295 are referrals to us from Jesse Ferrer.

Q Sir, are you now aware that while attending an American Association for Justice convention in July of 2010, Attorney Ferrer executed a protective order that is the form of protective order of PTO 10?

A Yes, from the documents that we've seen, on July 10th, 2010, which was essentially right about the time we got our settlement done in principle, Jesse was at an AAJ convention sitting in a seminar.

Before they put materials on the screen he insisted that everybody in that room sign this document that he signed. It is my understanding he signed it

Mr. Garrison - Redirect

39

23

24

25

1 and they just took it up, and that was the end of that. 2 So, when I had asked Jesse whether or not he 3 ever agreed to anything to pay MDL fees, he told me no, 4 he had just forgotten that he ever signed such a 5 document because he didn't -- a copy was not provided 6 to them. 7 Sir, let me be very clear about this, because of a 8 filing that we filed on behalf of your firm, did assert that your firm was not aware of anybody with a fee 10 interest in your cases having signed such a protective 11 order. 12 Subsequent to our filing before this Court 13 you have, in fact, now seen documents that were provided by the PAC as a matter of fact, indicating 14 that Mr. Ferrer did, in fact, sign that on July 10th, 15 16 2010, is that correct, sir? Yes, sir. None of our referring attorneys to our 17 knowledge had ever signed anything agreeing to pay any 18 19 assessment to the PSC, and when we had asked that question of Mr. Ferrer he responded to us that he had 20 not signed any such thing. 21 22

In fact, it wasn't until we were produced -until the endorsement of the PTO was produced that he
signed on July 10th, that was the first knowledge we
certainly ever had.

## Mr. Garrison - Redirect

In fact, Jesse confirmed that he had forgotten he even signed such a thing because of the circumstances under which it was signed.

Q And just so it's clear from the chronological order of how this happened, because I've asked you this series of questions about Attorney Ferrer out of the sequence of the other things that happened.

Where in the sequence of your negotiations and the motions you were filing against GSK did that happen, is it before or after you actually had an agreement as to the number with GSK?

A Well, we reached an agreement with GSK through its agent, I suppose, Mike Rosen, in early July where we agreed what the settlement number would be for our 679 cases, and also the per case average for what that would be.

Then, of course, what followed was I suppose Mr. Rosen got in touch with GSK and then Ken Zucker sent us the first draft of the master settlement agreement on July 17th.

In fact, if you look at that first draft of the master settlement agreement that we received on July 17th and compare it to our file version, which was achieved some few months later, very few terms were changed, and certainly no substantive terms were

## Mr. Garrison - Redirect 41 1 changed. 2 Sir, to your knowledge was there any interaction 3 whatsoever with Jesse Ferrer regarding any information 4 that had been presented to him at that AAJ convention 5 regarding privileged documents at any time before you 6 reached your settlement in principle with GSK? 7 Absolutely not. 8 All right. 9 I had no idea Jesse had even attended such a 10 seminar, and no, he didn't give us any information 11 whatsoever. 12 MR. SACHS: Nothing further on behalf of the 13 Heninger Garrison firm, Your Honor. 14 THE COURT: Thank you. Redirect. 15 MR. ZONIES: Thank you, Your Honor. I will 16 start by moving for admission of the endorsement of 17 protective order 10 executed by Mr. Ferrer as PAC-4. 18 May I approach, Your Honor? 19 THE COURT: Yes. Thank you. 20 (Pause in proceedings.) 21 THE COURT: Any objection, Mr. Sachs? MR. SACHS: Sorry, Your Honor, I should have 22 23 risen before. No objection. 24 THE COURT: It is admitted. 25 (Plaintiffs' Exhibit PAC-4, endorsement, is

42 Mr. Garrison - Redirect 1 admitted into evidence.) 2 **RECROSS-EXAMINATION** 3 BY MR. ZONIES: Mr. Garrison, you on behalf of your firm and 4 clients, had set the resolution of the assessment issue 5 6 for a motions hearing in Alabama, correct? 7 We had tried to do that, yes, sir. 8 And that court eventually entered an order 9 continuing that hearing generally, correct? 10 It did. 11 And as part of that order, the court stated that "To answer the question before this Court as to whether 12 or not the claim inventory represented by Heninger 13 14 attorneys are subject to PTO's common benefit 15 assessment. "This Court is of the opinion that this 16 question should only be considered and answered by the 17 MDL Court in the Eastern District of Pennsylvania." Is 18 that what that court stated? 19 I do not have an order here in front of me, Mr. 20 Zonies, but from my recollection that does sound 21 22 correct. (Pause in proceedings.) 23 MR. ZONIES: We move for admission of that 24 order as PAC-5, Your Honor. 25

```
FORM 2094 🍪 PENGAD + 1-800-631-6989 • www.pengad.com
```

```
Mr. Garrison - Recross
                                                            43
 1
               MR. SACHS: No objection.
 2
               THE COURT: Thank you. It is admitted.
 3
               (Plaintiffs' Exhibit PAC-5, court order, is
 4
    admitted into evidence.)
 5
               MR. ZONIES: May I approach?
 6
               THE COURT: Yes.
 7
               MR. ZONIES: Thank you.
 8
               (Pause in proceedings.)
 9
    BY MR. ZONIES:
10
         Are you prepared, Mr. Garrison, to dismiss that
    with prejudice at this time?
12
         To dismiss what with prejudice?
13
         The state court motion seeking that court's
14
    findings on whether or not Heninger Garrison and his
15
    clients are subject to the assessment?
16
        Well, I suppose that would be the result if I
17
    agreed, which I've said I would do, transfer the seven
    percent to whatever account Judge Rufe wants me to
18
    transfer it to. So, that would moot that motion, in my
19
20
    opinion.
        You will agree to pull that motion down?
21
         The motion, any motion dealing with his
22
    interpretation of whether or not I need to pay the
23
    seven percent, yes, sir.
24
               You know, this still is somewhat if a
25
```

Mr. Garrison - Recross 44 1 sticky-wicket with the state court having a qualified 2 settlement fund, but like I just testified to I am 3 certainly happy to transfer whatever that money is up 4 to your account and get it resolved through Judge 5 Rufe's --6 THE COURT: Excuse me, Mr. Garrison, this is 7 the Judge. I don't think the camera is on me. 8 THE WITNESS: Yes, ma'am? 9 THE COURT: But, that's all right. I wanted 10 to just clarify something. As I read your QSF, at 11 least the pertinent part, releases of funds can be 12 authorized by joint signature of yourself, your firm, 13 and GSK, isn't that correct? 14 THE WITNESS: Yes, ma'am. Once we had the 15 original distribution that the judge signed off on, 16 then my recollection is, Judge Rufe, that there was an 17 order that was part of Judge Brown's order that any 18 future distributions we could just agree to between 19 ourselves, and we did not need the court's 20 involvement. THE COURT: I think I read that, as well. 21 So, there is a way to mechanically take care of this 22 issue without further motioning any court, isn't that 23 the case?

THE WITNESS: In my understanding, yes,

25

24

25

released, correct?

Mr. Garrison - Recross 45 1 I am willing to do it. ma'am. 2 THE COURT: That would alleviate Judge Brown 3 from being in the position of having to enter an order 4 or enter rulings that would make the state court look 5 as if it was exercising some type of jurisdiction on 6 this issue, and in your position would that not be 7 preferable, at least for that court, given his order 8 entered June 27th? 9 THE WITNESS: Your Honor, yes, ma'am. What I 10 would prefer to do would just be a document signed by 11 my firm and Mr. Zucker agreeing to transfer whatever 12 the sum of money is. 13 THE COURT: All right. Thank you. Mr. 14 Zonies, I interrupted you. 15 THE WITNESS: Thank you. 16 MR. ZONIES: That's fine, Your Honor, I appreciate that clarification on the Court's behalf. 17 BY MR. ZONIES: 18 Mr. Heninger, just to be clear -- I'm sorry, Mr. 19 Garrison, just to be clear, to have release of those 20 funds from that QSF there are two parties that must 21 agree those funds? 22 In other words, GSK must agree to release 23

those funds from the QSF in order for those funds to be

```
Mr. Garrison - Recross
                                                           46
 1
    Α
        Yes, sir.
 2
        And absent GSK's action to release those funds, the
 3
    funds would not come out of that QSF, correct?
 4
        I haven't figured a way to get the money without
 5
    GSK's authorization so far.
 6
              MR. ZONIES: Nothing more on that, Your
7
    Honor.
8
              THE COURT:
                           Thank you.
9
              MR. ZONIES: Thank you.
10
              THE WITNESS: By the way, Mr. Zonies, there
11
    is also a settlement administrator that was appointed
12
    by Judge Brown. He may need to sign off on it.
13
               I don't think so, but I don't want to just
14
    say, you know, here in court that we just forget him.
15
    But, I don't think he has to sign off on it, but we can
16
    check that out.
              MR. ZONIES: I'm not so sure the Court would
17
    have jurisdiction over him, but I'm certainly confident
18
    the Court would have the jurisdiction over GSK. So,
19
    thank you for that clarification, Mr. Garrison.
20
               THE COURT: Thank you. We agree with that
21
    observation. Any redirect from GSK on this issue?
22
              MS. GUSSACK: No, Your Honor.
23
               THE COURT: All right. I'm sorry, I meant
24
```

Any redirect?

cross.

25

```
Mr. Garrison - Recross
                                                           47
1
              MR. SACHS: No, Your Honor, nothing further
2
    at this time.
3
              THE COURT: All right. Mr. Garrison, is
4
    there anything else you would like to say before we
5
    allow you to step down as a witness?
6
              THE WITNESS: No, ma'am, but I do appreciate
7
    your accommodation, Judge Rufe, and sorry to put you
8
    out and have you come in to do this, and this is my
9
    first video link. It's very interesting, to say the
10
    least.
11
              THE COURT:
                           It does work.
12
              THE WITNESS:
                             It does.
13
              THE COURT: Usually, we reserve it for
14
    prisoners.
15
              THE WITNESS:
                             Whoops.
16
              MR. SACHS: As your attorney I advise you not
17
    to comment.
18
               THE COURT: We find it helpful, especially
    when managing MDLs to include as many counsel and even
19
    parties across the country, because that is what we do.
20
21
    We include, not exclude.
               THE WITNESS: Yes, ma'am.
22
23
               THE COURT: We like to resolve cases. I hope
    that the next time we interface it will be in a
24
    different and on a different issue. But, I hope that
25
```

```
1
    something is carried away from this, Mr. Garrison.
2
              I think we could have reached this resolution
3
    even without a hearing some time ago. I don't think it
4
    had to involve two courts in two different
5
    jurisdictions.
6
              Nevertheless, Judge Brown, being the gracious
7
    judge and I think astute judge that he is, recognized
8
    that it was something that the MDL had to handle. I
9
    hope that in the future we don't have these
10
    misunderstandings, in any event.
11
              THE WITNESS:
                            Thank you, Your Honor.
12
              THE COURT: Thank you.
              THE WITNESS:
                             I thank you.
13
14
              THE COURT: Good luck to you and your family.
              THE WITNESS: Thank you, ma'am, I sure
15
16
    appreciate it.
              THE COURT: All right. You may stay where
17
    you are because you are still participating as a party
18
    while we conduct the remainder of this hearing.
19
              Mr. Sachs, do you have anything else to
20
    present?
21
              MR. SACHS: We do not, Your Honor.
22
               THE COURT: Thank you. Mr. Zonies, do you
23
    have anything else to present?
24
              MR. ZONIES: Your Honor, we are prepared to
25
```

put on for the Court testimony concerning the work of the MDL over the entire span of the MDL.

But, we can't anticipate that the Court understands most of it, if not all of it, in a summary fashion if the Court so desires. If so, I would ask for five minutes to just discuss with my co-counsel.

THE COURT: Let's take a recess, discuss it with your co-counsel. A summary fashion would be acceptable. I don't think we need the long version today. We are in brief recess.

(Recess, 10:35 a.m. to 10:51 a.m.)

THE COURT: It's still good morning. Please be seated. On behalf of the plaintiffs' advisory committee?

MR. ZONIES: Your Honor, Joe Zonies. Your Honor, upon further reflection and review of this Court's order setting this hearing and discussions with Mr. Sachs, we have determined that we believe that the Court has sufficient information at this time to make its determinations as limited in this Court's order, which were, and I quote from the Court's order entered on the 25th of June of this year. It states as follows.

"The MDL Court will hold a hearing on the interpretation and the application of PTO 70 to the

1 Heninger settlement on July 2nd.

"The hearing will include the development of a factual record regarding whether any attorney with a fee interest in the Heninger claims executed in the endorsement of protective order attached to PTO 10, or the participation agreement attached to PTO 70."

We believe at this time that the factual basis for that is before the Court, and we would suggest that in order to keep this being resolved in the morning, that the PAC has no further evidence to put on.

THE COURT: Thank you. Would GSK have any evidence to present?

MS. GUSSACK: No, Your Honor.

THE COURT: Thank you. Back to you and your rebuttal.

MR. SACHS: Of course not, based on the presentation as the evidence has come in, Your Honor.

THE COURT: Thank you. The evidence is closed.

We accept the position of all of the parties, and I believe that is appropriate for the matter at hand to enter a written ruling filed with the MDL and on the website for all other participants and interested parties to see.

So, we will do that as a matter of record. A transcript of this proceeding will also be posted on PACER. I think that's routine these days, unless there is some reason not to. But, I can't see that reason now.

I think that it is important to note on this record now while we are all here together that although the parties have concurred and agreed, in particular the Heninger Garrison Davis, LLC firm and Mr. Garrison himself, have agreed that this Court has the appropriate jurisdictional base to address this matter. That is, the assessment of the common fund, seven percent or any number thereof.

I believe it is also important for the Court to conduct its own inquiry. This hearing has provided the Court with a factual basis to support that concurrence by counsel and the parties.

We exercise the jurisdiction of the MDL court, that is the federal court, and accept the testimony of all parties and witnesses today, along with the documents that have been presented by agreement.

We find that Mr. Garrison and his firm's cases, totaling 503 cases, are hereby subject to the assessment on each case of the seven percent fee when

and as appropriate, that is with the signatures of both Mr. Garrison and GSK, those funds can be released forthwith, we would like to believe, to the settlement fund conducted and monitored by Andy Chirls named as the settlement administrator for the MDL.

So, they will be directed, those funds, to be transferred by signature. I do not know what else would be needed, but if the Jefferson County qualified settlement fund needs more I will communicate with Judge Brown if that is what they need, but I do not think that is what they should need based on the joint signature provision and Judge Brown's earlier order. So, hopefully he will be spared.

I also direct that Mr. Garrison withdraw with prejudice the pending motion before the Jefferson County Court, and this ruling may not apply to all matters involving the QSF and Jefferson County, but it does matter and it does apply to the common fee assessment that is due and owing to the MDL created common fund. The disbursements thereafter will be according to the orders that we have already established.

Now, I would like to review the record to make sure that further findings may be in order. We do find and want to reiterate that attorneys who sign the

endorsement for Pretrial Order Number 10, which is a confidentiality provision, the protective order, are subjecting themselves and their cases, whether they are referred out to other firms or not, to the MDL's jurisdiction to determine these types of issues.

We also find that Pretrial Order Number 10, the protective order and its endorsement work in conjunction with PTO 70, and PTO 70 itself has a number of provisions that would cause the MDL to exercise jurisdiction over its enforcement. We are satisfied that in this case there are several bases to enforce.

One problematic factual matter has been brought to this Court's attention by the testimony of Mr. Garrison. I'll tell you why it is problematic in a moment. It's not problematic to my determination of having jurisdiction, it's not problematic for my determination of the seven percent assessment which has been agreed to by Mr. Garrison on each and every one of his settled cases.

It is that Mr. Garrison has represented that he has settled these cases, now publicly and on the record, without having any discovery documents. It is hard for this Court to countenance that.

It is not that I don't believe Mr. Garrison, it is that it is probably not the way I would hope that

cases are resolved. Too often I see inventories of cases that are not really worked up past the plaintiff fact sheet.

I hope that practice does not continue in this or any other MDL. I know it exists out in the world. I am not sure that it is the way that justice is achieved. I know it is not common practice, but I do see it happening.

It happens as a result of large inventories of cases being handled. They can be handled by appropriate resources and attorneys that devote those resources and their firm to preparation of their cases enough to know whether to settle or not.

But, I don't think it is a basis upon which I will ever be able to say you don't owe the seven percent or any part thereof because you didn't use discovery.

I don't know how you represent anyone without some understanding of the facts and, Mr. Garrison, you and your firm are well-known in MDL circles. I believe you prepare your cases better than that.

So, this is going to be a warning to all those out there in MDL land and in any MDL that I have anything to do with, that I expect attorneys will work their cases and control the numbers of their

```
55
1
    inventories to do so.
2
               That's probably not on-point, as they say,
    but it is an observation that I feel compelled to make
3
    on the record. Is there anything anyone would like to
4
5
    say?
6
               MR. SACHS: No, Your Honor.
7
               MR. ZONIES: Nothing, Your Honor.
8
               MS. GUSSACK: No, Your Honor.
9
               THE COURT: We are adjourned.
10
               (Proceedings adjourned at 11:00 a.m.)
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```

## CERTIFICATION

I, Jeff Nathanson, do hereby certify that the foregoing is a true and correct transcript from the electronic sound recordings of the proceedings in the above-captioned matter.

7-20-15 Date

Jets/Nathanson